Literature DB >> 26668254

Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.

Núria Buil-Bruna1, José-María López-Picazo2, Salvador Martín-Algarra2, Iñaki F Trocóniz3.   

Abstract

UNLABELLED: Despite much investment and progress, oncology is still an area with significant unmet medical needs, with new therapies and more effective use of current therapies needed. The emergent field of pharmacometrics combines principles from pharmacology (pharmacokinetics [PK] and pharmacodynamics [PD]), statistics, and computational modeling to support drug development and optimize the use of already marketed drugs. Although it has gained a role within drug development, its use in clinical practice remains scarce. The aim of the present study was to review the principal pharmacometric concepts and provide some examples of its use in oncology. Integrated population PK/PD/disease progression models as part of the pharmacometrics platform provide a powerful tool to predict outcomes so that the right dose can be given to the right patient to maximize drug efficacy and reduce drug toxicity. Population models often can be developed with routinely collected medical record data; therefore, we encourage the application of such models in the clinical setting by generating close collaborations between physicians and pharmacometricians. IMPLICATIONS FOR PRACTICE: The present review details how the emerging field of pharmacometrics can integrate medical record data with predictive pharmacological and statistical models of drug response to optimize and individualize therapies. In order to make this routine practice in the clinic, greater awareness of the potential benefits of the field is required among clinicians, together with closer collaboration between pharmacometricians and clinicians to ensure the requisite data are collected in a suitable format for pharmacometrics analysis. ©AlphaMed Press.

Entities:  

Keywords:  Biological and disease models; Computer simulations; Individualized medicine; Patient-specific modeling

Mesh:

Substances:

Year:  2015        PMID: 26668254      PMCID: PMC4746090          DOI: 10.1634/theoncologist.2015-0322

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  80 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Authors:  Wim H J Kruit; Heidi H van Ojik; Vincent G Brichard; Bernard Escudier; Thierry Dorval; Brigitte Dréno; Poulam Patel; Nicolas van Baren; Marie-Françoise Avril; Sophie Piperno; Amir Khammari; Marguerite Stas; Gerd Ritter; Bernard Lethé; Danièle Godelaine; Francis Brasseur; Yi Zhang; Pierre van der Bruggen; Thierry Boon; Alexander M M Eggermont; Marie Marchand
Journal:  Int J Cancer       Date:  2005-11-20       Impact factor: 7.396

3.  Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.

Authors:  P Jacqmin; E Snoeck; E A van Schaick; R Gieschke; P Pillai; J-L Steimer; P Girard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-19       Impact factor: 2.745

Review 4.  A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment.

Authors:  R Almufti; M Wilbaux; A Oza; E Henin; G Freyer; M Tod; O Colomban; B You
Journal:  Ann Oncol       Date:  2014-01       Impact factor: 32.976

5.  Mechanism-based models for topotecan-induced neutropenia.

Authors:  Frédéric Léger; Walter J Loos; Roland Bugat; Ron H J Mathijssen; Marine Goffinet; Jaap Verweij; Alex Sparreboom; Etienne Chatelut
Journal:  Clin Pharmacol Ther       Date:  2004-12       Impact factor: 6.875

6.  Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

Authors:  Charlotte van Kesteren; Anthe S Zandvliet; Mats O Karlsson; Ron A A Mathôt; Cornelis J A Punt; Jean-Pierre Armand; Eric Raymond; Alwin D R Huitema; Christian Dittrich; Herlinde Dumez; Henri H Roché; Jean-Pierre Droz; Miroslav Ravic; S Murray Yule; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

7.  Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.

Authors:  Solène Desmée; France Mentré; Christine Veyrat-Follet; Jérémie Guedj
Journal:  AAPS J       Date:  2015-03-05       Impact factor: 4.009

8.  Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.

Authors:  Rujia Xie; Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij; Mats O Karlsson
Journal:  Clin Pharmacol Ther       Date:  2002-09       Impact factor: 6.875

Review 9.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Authors:  Brett E Houk; Carlo L Bello; Bill Poland; Lee S Rosen; George D Demetri; Robert J Motzer
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-05       Impact factor: 3.333

10.  PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.

Authors:  E K Hansson; G Ma; M A Amantea; J French; P A Milligan; L E Friberg; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-12-04
View more
  15 in total

1.  Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach.

Authors:  Belén P Solans; Ascensión López-Díaz de Cerio; Arlette Elizalde; Luis Javier Pina; Susana Inogés; Jaime Espinós; Esteban Salgado; Luis Daniel Mejías; Iñaki F Trocóniz; Marta Santisteban
Journal:  Br J Clin Pharmacol       Date:  2019-06-14       Impact factor: 4.335

Review 2.  Looking beyond the hype: Applied AI and machine learning in translational medicine.

Authors:  Tzen S Toh; Frank Dondelinger; Dennis Wang
Journal:  EBioMedicine       Date:  2019-08-26       Impact factor: 8.143

3.  Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Curr Pharmacol Rep       Date:  2018-05-03

Review 4.  Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.

Authors:  Stephanie Faucette; Santosh Wagh; Ashit Trivedi; Karthik Venkatakrishnan; Neeraj Gupta
Journal:  Clin Transl Sci       Date:  2017-12-19       Impact factor: 4.689

5.  Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling.

Authors:  Patricia Martin-Romano; Belén P Solans; David Cano; Jose Carlos Subtil; Ana Chopitea; Leire Arbea; Maria Dolores Lozano; Eduardo Castanon; Iosune Baraibar; Diego Salas; Jose Luis Hernandez-Lizoain; Iñaki F Trocóniz; Javier Rodriguez
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

Review 6.  Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development.

Authors:  Gabriel Helmlinger; Victor Sokolov; Kirill Peskov; Karen M Hallow; Yuri Kosinsky; Veronika Voronova; Lulu Chu; Tatiana Yakovleva; Ivan Azarov; Daniel Kaschek; Artem Dolgun; Henning Schmidt; David W Boulton; Robert C Penland
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-06-11

7.  Emerging roles for clinical pharmacometrics in cancer precision medicine.

Authors:  Sujit Nair; Ah-Ng Tony Kong
Journal:  Curr Pharmacol Rep       Date:  2018-04-20

Review 8.  In silico cancer research towards 3R.

Authors:  Claire Jean-Quartier; Fleur Jeanquartier; Igor Jurisica; Andreas Holzinger
Journal:  BMC Cancer       Date:  2018-04-12       Impact factor: 4.430

9.  Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse.

Authors:  Pablo Sala Elarre; Esther Oyaga-Iriarte; Kenneth H Yu; Vicky Baudin; Leire Arbea Moreno; Omar Carranza; Ana Chopitea Ortega; Mariano Ponz-Sarvise; Luis D Mejías Sosa; Fernando Rotellar Sastre; Blanca Larrea Leoz; Yohana Iragorri Barberena; Jose C Subtil Iñigo; Alberto Benito Boíllos; Fernando Pardo; Javier Rodríguez Rodríguez
Journal:  Cancers (Basel)       Date:  2019-04-30       Impact factor: 6.639

10.  Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen.

Authors:  Lena Klopp-Schulze; Anna Mueller-Schoell; Patrick Neven; Stijn L W Koolen; Ron H J Mathijssen; Markus Joerger; Charlotte Kloft
Journal:  Front Pharmacol       Date:  2020-03-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.